Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in serious adverse events WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with formoterol (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Serious adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events—'serious' Duration of two years1 · COPD
Fluticasone/salmeterol (FPS) showed no clear difference in adverse events—'serious' Duration of two years1 compared with placebo (low certainty).
1 finding from 1 review
OR 1.08 [0.95, 1.23]
5531 participants
Low
Adverse events—'serious'—320/94 Duration of 10 months3 · COPD
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—320/94 Duration of 10 months3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.17 [0.95, 1.45]
2476 participants
Low
Intervention not reported
Serious adverse events ‐ Haemodilution versus control. · patients with liver resection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events—'serious'—160/94 Duration of nine months 3 · COPD
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—160/94 Duration of nine months 3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.2 [0.89, 1.63]
1556 participants
Low
Number of participants experiencing any serious adverse events · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in serious adverse events (number of people experiencing ≥ 1 SAEs) compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events－serious Mometasone/formoterol (MF/F) versus Mometasone (MF) · patients with COPD
The intervention showed no clear difference in adverse events－serious Mometasone/formoterol (MF/F) versus… (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events－serious Fluticasone/salmeterol (FPS) versus fluticasone (FP) · patients with COPD
The intervention showed no clear difference in adverse events－serious Fluticasone/salmeterol (FPS) versus… (low certainty).
1 finding from 1 review